MANGOCEUTICALS INC. -

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

03 10 2024 08:30:00 提供 Nasdaq GlobeNewswire

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

01 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

15 8 2024 09:25:00 提供 Nasdaq GlobeNewswire

MangoRx Receives Certificate of Grant in India for its Respiratory Illness and Preventive Care Technology Patent

13 8 2024 16:00:00 提供 Nasdaq GlobeNewswire

MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide

09 8 2024 08:15:00 提供 Nasdaq GlobeNewswire

MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology

24 7 2024 08:15:00 提供 Nasdaq GlobeNewswire

Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access

18 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

16 7 2024 08:20:00 提供 Nasdaq GlobeNewswire

MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

12 7 2024 13:30:00 提供 Nasdaq GlobeNewswire

MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets

11 7 2024 08:15:00 提供 Nasdaq GlobeNewswire

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

06 6 2024 08:30:00 提供 Nasdaq GlobeNewswire

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

04 6 2024 16:00:00 提供 Nasdaq GlobeNewswire

MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

04 6 2024 08:00:01 提供 Nasdaq GlobeNewswire

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets

28 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

23 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

21 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

16 5 2024 16:40:00 提供 Nasdaq GlobeNewswire

Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement

02 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care

25 4 2024 08:30:00 提供 Nasdaq GlobeNewswire

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

12 4 2024 08:45:00 提供 Nasdaq GlobeNewswire